AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/9/2026

1. USO
2. MSFT
3. META
4. COST
5. SPY
6. MU
7. RMR
8. LEVI
9. RXT
10. AAPL

Go back to AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture

Oppenheimer Upgrades AngioDynamics (ANGO) to Outperform

April 5, 2024 7:02 AM EDT

Oppenheimer analyst Steven M. Lichtman upgraded AngioDynamics (NASDAQ: ANGO) from Perform to Outperform with a price target of $12.00.

The analyst comments "We are upgrading ANGO shares from Perform to Outperform with a $12 PT based on the following: 1) Yesterday's earlier than expected FDA approval... More

AngioDynamics (ANGO) Misses Q3 EPS by 2c

April 4, 2024 7:36 AM EDT

AngioDynamics (NASDAQ: ANGO) reported Q3 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $66 million versus the consensus estimate of $75.73 million.

GUIDANCE:

AngioDynamics sees FY2024 EPS of ($0.54)-($0.58), versus the consensus of ($0.43). AngioDynamics sees... More